Advances in atopic dermatitis in 2015 - 18/04/17
Abstract |
This review aims to highlight recently published articles on atopic dermatitis (AD). Updated are the insights into epidemiology, pathology, diagnostics, and therapy. Epidemiologic studies have revealed a positive correlation between AD and systemic conditions, such as rheumatoid arthritis, inflammatory bowel disease, and neonatal adiposity. Pathologic findings highlight the involvement of novel barrier factors (desmoplakin and claudin), novel immune cell subsets (pathogenic effector TH2 cells and group 2 innate lymphoid cells), and differential skewing of helper T cells (eg, TH17 dominance in Asians with AD). As diagnostics, noninvasive examinations of the transepidermal water loss of neonates, the density of epidermal Staphylococcus species, and the gut flora might prognosticate the onset of AD. As for therapy, various methods are proposed, including conventional (petrolatum and UV) and molecule-oriented regimens targeting Janus kinase, signal transducer and activator of transcription 3, extracellular signal-regulated kinase, sirtuin 1, or aryl hydrocarbon receptor.
El texto completo de este artículo está disponible en PDF.Key words : Atopic dermatitis, filaggrin, biologics, cytokines, chemokines, thymic stromal lymphopoietin, chemoattractant receptor-homologous molecule expressed on TH2 cells, petrolatum, ultraviolet B, sirtuin 1, aryl hydrocarbon receptor, Janus kinase, signal transducer and activator of transcription 3, extracellular signal-regulated kinase, pathogenic effector TH2, TH1, TH2, TH17, TH22, transepidermal water loss, adiposity, JTE-052
Abbreviations used : AD, aOR, APT, CLA, CRTH2, FLG, GWAS, ILC, IRR, KYNU, OR, peTH2, RR, SCORAD, SNP, STAT, TSLP
Esquema
Supported in part by the Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research (15H05790, 24591649, and 15K09765); Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research on Innovative Areas (15H1155); Japan Society for the Promotion of Science, Grant-in-Aid for challenging Exploratory Research (15K15417); Japan Science and Technology Agency, Precursory Research for Embryonic Science and Technology (PRESTO) (16021031300); and Japan Agency for Medical Research and Development (AMED; 16ek0410011h0003, 16he0902003h0002). |
|
Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
Vol 138 - N° 6
P. 1548-1555 - décembre 2016 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?